Taiwan’s Foresee Pharmaceuticals Co Ltd (TWO:6576) said on Friday that the U.S. Food and Drug Administration had approved its CAMCEVI ETM injection for the treatment of advanced prostate cancer.
Foresee said in a press release the FDA had approved its new drug application for CAMCEVI, following a successful phase 3 trial for the treatment. The trial had demonstrated endpoint efficacy in 97.9% of subjects tested.
Foresee said commercial launch of the treatment will take place after it receives a J-code for CAMCEVI ETM. The treatment is exclusively licensed to Accord BioPharma, a unit of Intas Pharmaceuticals, for commercialization in the United States.
Source :
https://www.investing.com/news/stock-market-news/taiwans-foresee-pharma-announces-fda-approval-of-prostate-cancer-treatment-4215778
